 NIM811 is a form of treatment for patients with the hepatitis C virus (HCV).Studies indicate a strong relationship between a treatments cyclophilin binding affinity and suppression of HCV activity.NIM811 is also being studied as a potential treatment to genetic muscular diseases such as Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) disease, diseases altering the genes for collagen VI production.